Product development

Aduro Biotech Europe, a subsidiary of U.S.-based Aduro Biotech, is focused on the development of B-select monoclonal antibodies (mAB) for the treatment of cancer and other serious conditions. The lead B-select program is BION-1301, an anti-APRIL antibody expected to enter clinical development for the treatment of multiple myeloma in late 2017.

Email: aduraeurope@aduro.com

The B-select technology is a key component of Aduro’s ’ development pipeline, which also consists of LADD (live, attenuated double-deleted Listeria monocytogenes) and STING Pathway Activators. Collectively, Aduro’s three technology platforms are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth. To learn more, visit www.aduro.com.

Area of work

Oncology, Immunology, Antibodies, Drug development

Drug development Pipeline

Target discovery – Clinical development

``Here are facilities that are not available anywhere else. The Pivot Park Screening Centre (PPSC) is a good example of this. PPSC has a collection of more than 300,000 compounds that can serve as a starting point for new medicines. Here, as a life science entrepreneur, you can have your target screened and have your own new compounds tested. ``

News from Aduro Biotech Europe

Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma

11 Feb 19
READ MORE

Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer

12 Jun 18
READ MORE

Aduro Announces Milestone Achieved under Merck Collaboration for Initiation of Anti-CD27 Phase I Trial in Advanced Solid Tumors

07 Mar 18
READ MORE